| 51 |
14632720 | Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. | 2003 Nov |
1 |
| 52 |
11815507 | Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. | 2002 Feb |
1 |
| 53 |
12073790 | [Postprandial hyperglycemia. II. Pharmacological approaches]. | 2002 Apr |
3 |
| 54 |
12189909 | Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications. | 2002 Apr |
1 |
| 55 |
12196472 | Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. | 2002 Sep |
1 |
| 56 |
12351462 | Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. | 2002 Oct |
1 |
| 57 |
12432213 | Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. | 2002 Jul-Sep |
1 |
| 58 |
12702002 | Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes. | 2002 Dec |
1 |
| 59 |
12702004 | Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. | 2002 Dec |
5 |
| 60 |
11194245 | Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. | 2001 Jan |
1 |
| 61 |
11460577 | Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers. | 2001 |
1 |
| 62 |
11483229 | Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. | 2001 Sep |
2 |
| 63 |
11525087 | [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2]. | 2001 Aug 11 |
1 |
| 64 |
11574430 | Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. | 2001 Oct |
2 |
| 65 |
11577798 | Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. | 2001 |
2 |
| 66 |
10664920 | Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease. | 2000 Feb |
2 |
| 67 |
10834429 | Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency. | 2000 May |
8 |
| 68 |
10857945 | Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. | 2000 Apr |
5 |
| 69 |
10872292 | [Therapy of type 2 diabetes. Critical evaluation of oral antidiabetic drugs]. | 2000 May 25 |
1 |
| 70 |
10929931 | A rational approach to drug therapy of type 2 diabetes mellitus. | 2000 Jul |
1 |
| 71 |
10959157 | [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients]. | 2000 Jul 20 |
2 |
| 72 |
11060717 | Pharmacology and clinical experience with repaglinide. | 2000 Apr |
2 |
| 73 |
11063282 | The importance of early insulin secretion and its impact on glycaemic regulation. | 2000 Sep |
2 |
| 74 |
11190420 | Meglitinide analogues in the treatment of type 2 diabetes mellitus. | 2000 Nov |
1 |
| 75 |
11225759 | Repaglinide: prandial glucose regulation in clinical practice. | 2000 Mar |
1 |
| 76 |
11249478 | A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. | 2000 Dec |
2 |
| 77 |
10333912 | Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. | 1999 Jan |
1 |
| 78 |
10501822 | Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing. | 1999 Sep |
1 |
| 79 |
10522838 | Repaglinide as monotherapy in Type 2 diabetes. | 1999 |
3 |
| 80 |
10605995 | Oral pharmacologic management of type 2 diabetes. | 1999 Dec |
1 |
| 81 |
10746004 | [Mechanisms of action of repaglinide at a cellular level]. | 1999 Dec |
2 |
| 82 |
10820647 | Recent developments and emerging therapies for type 2 diabetes mellitus. | 1999 Aug |
1 |
| 83 |
11220287 | Promising new approaches. | 1999 May |
1 |
| 84 |
11475269 | Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes. | 1999 Fall |
1 |
| 85 |
9739505 | Repaglinide. | 1998 Aug |
1 |
| 86 |
9802740 | A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. | 1998 Nov |
1 |
| 87 |
9855316 | Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. | 1998 Nov-Dec |
3 |
| 88 |
9657067 | Stimulation of insulin and somatostatin release by two meglitinide analogs. | 1997 Dec |
2 |
| 89 |
15989662 | New non-sulfonylurea insulin secretagogues. | 1997 Aug |
1 |
| 90 |
8944206 | New treatments for patients with type 2 diabetes mellitus. | 1996 Nov |
1 |
| 91 |
8223830 | Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. | 1993 |
1 |